Home > Remibrutinib

molecules of the month

Remibrutinib

BTK-selective covalent kinase inhibitor

Ph. I completed in HV, in Ph. II

SBDD from reversible BTK inhibitor and opt.

J. Med. Chem., Mar. 4, 2020

Novartis, Basel, CH

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.